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sEverything should be made as simple as possible,
but not simpler.
—Albert Einstein (1)
The literature on response failure of cardiac resyn-
chronization therapy (CRT) has identified a num-
ber of potential contributors, including excessive
left ventricular (LV) remodeling, location of the
pacing lead, and a variety of problems related to
mechanical dyssynchrony, including failure to opti-
mize resynchronization (2). However, the presence
See page 366
of extensive scar and lack of contractile reserve (3),
especially the presence of scar at the pacing site
(4,5), is readily understandable as a cause for CRT
nonresponse. There exist a plethora of tests for
myocardial viability, and most have been used in the
evaluation of potential CRT response (4 –7).
Gadolinium-enhanced cardiac magnetic resonance
stands apart from the others in its intuitive simplic-
ity, to the extent that it has become the test of
choice for many clinicians. The principle of the test
relates to the entry of gadolinium in the extracellu-
lar space in areas of myocyte loss, and the resulting
contrast-enhanced signal is a well-validated marker
of scar extent. The problem with gadolinium-
enhanced cardiac magnetic resonance relates to
segments with intermediate levels of scar (8). In this
circumstance, a variety of tests have been used to
evaluate the nature of the remaining myocardium.
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eminal role in understanding how transmural
hickening can be used as a marker of the transmu-
al distribution of scar and likelihood of recovery
9,10).
In this issue of iJACC, Becker et al. (11) inves-
igate the role of myocardial viability on reverse
emodeling after CRT in patients with systolic
eart failure. In 65 heart failure patients studied
efore and 12 months after CRT implantation, the
ead was placed in a viable segment in 47, among
hom pacing was associated with more favorable
everse remodeling, improvement to ejection frac-
ion, and improvement of exercise capacity than
hen the lead was placed in a nonviable segment.
lthough the results confirm the role of preserved
yocardial viability at the site of CRT lead posi-
ion, the authors advance the field by applying
peckle tracking to assess not only mechanical
ispersion, but also segmental systolic circumferen-
ial strain as a marker of myocardial viability. The
nique role of strain analysis (rather than the
lternative modalities) is its ability to provide data
n dyssynchrony and viability to inform the optimal
acing site during CRT implantation. The infor-
ation provided may be especially important in
atients with ischemic cardiomyopathy.
Several aspects of the paper are particularly note-
orthy. First, it is important that these investigators
sed circumferential strain, rather than longitudinal
train, which has dominated the published reports
n strain. The reason that this is an important
evelopment is that longitudinal strain is primarily
marker of subendocardial function, and although
his appears to be the initial site of a variety of
ubclinical diseases (e.g., diabetes and hyperten-
ion), this is ill suited to viability assessment because
ubendocardial infarction causes reduction of this
arameter, with little additional change as scar
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376thickness increases (12). In contrast, the use of
radial or circumferential strain is better reflective of
the transmural extent of scar, and of the two,
circumferential strain appears to be the more ro-
bust. The same investigators have previously shown
in patients with myocardial infarction that a seg-
ment with circumferential strain 11.1% is likely
to be a transmural scar (9), and indeed, analysis of
the optimal cut-point in this group confirms that
this threshold is 11.9%. In the current era of
3-dimensional strain, a more sophisticated ap-
proach to the assessment of strain–multiple dimen-
sions may provide a more comprehensive means of
understanding the extent and location of scar.
Second, the investigators have applied the same
level of circumferential strain to responsiveness in
patients with nonischemic cardiomyopathy. These
findings infer a role for not just scar extent, but also
residual contractility, suggesting that impaired
function due to myocardial disease may have as
adverse an effect as scar. Several studies have shown
that the latest contracting LV segment can be used to
guide the LV lead position (13,14). It is not clear from
the current paper whether regional mechanical delay
(that is, the latest contracting LV segment) or viability
should be preferred for LV lead positioning.
So what is the future of imaging in the selection
of patients for CRT? The current indications for
CRT include patients with heart failure on appro-
priate medical therapy, with LV dysfunction, and a
wide QRS (0.12 s), without reference to mechan-
ical synchrony (15,16). There has been widespread
skepticism about the reliability of traditional echo-
cardiographic evaluation of mechanical dyssyn-
chrony since the PROSPECT (Predictors of Re-
sponse to CRT) study (17). Nonetheless, the
evaluation of CRT responsiveness remains a tanta-on clinical and echocardiographic im- Presence of left venis clouded by difficulties in defining responsiveness
(18), particularly in a patient group whose natural
history is often to experience progressive symptoms.
In such a context, failure to improve may not
necessarily represent treatment failure, if the natural
history in the absence of treatment might have been
inexorable deterioration. Nonetheless, this work
continues because although CRT offers clear prog-
nostic benefit in patients with heart failure (19–21),
for many of these elderly patients with comorbidi-
ties, symptom relief may be as (or even more)
important than prognostic benefit.
Unfortunately, although this rationale appears
reasonable, the evidence to support it is limited.
Some studies have shown that the use of multiple
synchrony markers improves the performance of
tests of mechanical synchrony (22,23). But the
dependence of the CRT response on many param-
eters suggests that the investigation of this approach
will require a multidimensional score that incorpo-
rates, not only synchrony, but the degree of LV and
right ventricular remodeling, scar extent and loca-
tion, pacing lead location, mechanical dyssyn-
chrony, and device optimization. The problem is
that a variety of investigations may be required to
derive all of the potentially relevant information,
ranging from echocardiography with tissue Doppler
or speckle imaging, computerized axial tomogra-
phy, myocardial scintigraphy, and cardiac magnetic
resonance. Many of these techniques can provide
information on more than 1 of these variables. The
paper by Becker et al. (11) is the start of such a
multiparametric approach from a single test.
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